PPARA and metabolic dysfunction-associated steatohepatitis: The resulting compound 41 was metabolically stable and non-toxic and engaged its molecular targets in cellular and in vivo settings demonstrating its suitability to further probe the concept of FXR/PPARα/δ activation in sophisticated in vivo models of NASH.